Virucidal activity of oral care products against SARS-CoV-2 in vitro

• Published in: Journal of oral and maxillofacial surgery, medicine, and pathology Vol. 33; no. 4; pp. 475 - 477
• Main Authors: Komine, Akihiko, Yamaguchi, Erika, Okamoto, Nako, Yamamoto, Kazushi
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 01.07.2021; Elsevier
• Subjects: CHX (chlorhexidine gluconate); CPC (cetylpyridinium chloride); Delmopinol hydrochloride; Original Research; SARS-CoV-2; Virucidal activity; SARS-CoV-2; Virucidal activity; CHX (chlorhexidine gluconate); CPC (cetylpyridinium chloride); Delmopinol hydrochloride
• ISSN: 2212-5558; 2212-5566
• DOI: 10.1016/j.ajoms.2021.02.002

Coronavirus disease 2019 (COVID-19) caused by infection by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide. Since reducing the amount of virus in saliva is considered to prevent broader infection, the Center for Disease Control (CDC) and American Dental Hygienists’ Association (ADHA) have recommended use of CPC- or CHX-containing oral care products before the dental procedure. However, there is no certified evidence. So, we examined inactivation of SARS-CoV-2 by oral care products in several countries in vitro. 0.05 % Cetylpyridinium chloride (CPC) mouthwash, 0.05 % CPC toothpaste and 0.30 % CPC spray in Japan; 0.06 % chlorhexidine gluconate (CHX) + 0.05 % CPC mouthwash and 0.12 % CHX + 0.05 % CPC mouthwash in Europe; 0.075 % CPC mouthwash, 0.12 % CHX mouthwash, and 0.20 % delmopinol hydrochloride mouthwash in the USA; and 0.04 % CPC mouthwash in China were assessed for their virucidal activity with ASTM E1052. The virus was inactivated in vitro by the contact time in directions for use of all oral care products containing CPC or delmopinol hydrochloride as anticeptics. These results suggest that these oral care products in each country may reduce the viral load in the mouth.